Bioavailability of Citrus Polymethoxylated Flavones and Their Biological Role in Metabolic Syndrome and Hyperlipidemia by Malkanthi Evans et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
14 
Bioavailability of Citrus  
Polymethoxylated Flavones and Their Biological 
Role in Metabolic Syndrome and Hyperlipidemia 
Malkanthi Evans, Prachi Sharma and Najla Guthrie 
KGK Synergize Inc. 
Canada 
1. Introduction 
Flavonoids are a group of polyphenolic compounds ubiquitous in many plants including 
fruits, vegetables, nuts, seeds, grains, tea and wine (Hollman & Katan, 1999). Flavonoids 
belong to two classes i) Flavanones and ii) Flavones. The most common flavanones are 
hesperetin from oranges and naringenin from grapefruit. The most common flavones, also 
known as polymethoxylated flavones, are tangeretin and nobiletin, present in orange and 
tangerine peel (Kurowska & Manthey, 2004).  
Recently, there has been an increasing interest in the health promoting properties of PMFs, 
which are known to play an important role in a number of biological functions as well as 
having anti-cancer (Silalahi, 2002), anti-inflammatory (Lin et al., 2003), and neuroprotective 
properties (Datla et al., 2001). Previously our team had performed pilot studies to 
investigate the biological properties of both nobiletin and tangeretin in small-animal and 
human clinical trials. Results of these studies have shown significant decreases in serum 
triglycerides, total cholesterol, and low density lipoprotein cholesterol and very low density 
lipoprotein cholesterol levels (Kurowska & Manthey, 2004; Roza et al., 2007) and increases in 
glucose tolerance (Li et al., 2006).  
Metabolic syndrome is a constellation of medical disorders that substantially increases the 
risk of individuals developing cardiovascular disease and diabetes. Metabolic syndrome has 
become increasingly common in Western society with a prevalence of 20-25% in the adult 
US population (Li et al., 2006). Early identification, prevention and treatment of metabolic 
syndrome portray a major challenge for the healthcare industry. During recent years, 
dietary supplements have been reported to be promising in reducing hyperglycemia and 
lipid disorders in individuals with type II diabetes or with predisposition to type II diabetes 
or hyperlipidemia. To date, little research has been conducted in investigating dietary 
supplements for their efficacy as hypolipidemic and antidiabetic therapeutic agents.  
Sufficient absorption of a drug or nutrient is important to obtain a successful therapeutic 
response. Bioavailability of a nutrient is simply the quantity or fraction of the ingested dose 
that is absorbed. Since oral bioavailability appears to be a limiting factor in the metabolism 
of citrus flavonoids and polyphenols, future studies are recommended to further investigate 
the biochemical factors influencing the bioavailibility of polymethoxylated flavones. This 
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chapter focuses on bioavailability of polymethoxylated flavones and presents results from in 
vitro, in vivo and human studies.  
2. Polymethoxylated flavones (PMFs)  
PMFs are a group of methoxylated phenolic compounds found exclusively in tissues and 
peels of Citrus reticulata (tangerine), Citrus paradisi (grapefruit), Citrus sinensis (sweet 
orange), and Citrus aurantium L. (sour orange) (Horowitz & Gentili, 1977; Dugo & McHale, 
2002). These various citrus species show very high variability in their content of PMFs. 
The main reason for the low oral bioavailability of the dietary flavonoids is the extensive 
conjugation of the free hydroxyl groups (Walle, et al., 2004; Manach & Donovan, 2004; 
Walle, et al., 2005). PMFs have a benzo-gamma-pyrone skeleton with a carbonyl group at 
the C-3 position and methoxy groups in different positions on the benzo-gamma-pyrone 
skeleton (Fig.1). The exclusive feature in the chemical structure of PMFs is the 
polymethylation of polyhydroxylated flavonoids, one of the major naturally occurring 
polyphenolic compounds. This results in increased metabolic stability and membrane 
transport in the intestine and liver, improving oral bioavailability (Walle, 2007).  
 
Fig. 1. Chemical structures of nobiletin and tangeretin (Ishii et al., 2010) 
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The two most common PMFs are nobiletin and tangeretin. They exhibit distinctive chemical 
and physical properties in comparison to other plant flavonoids which influence the 
metabolism and pharmacokinetics of these compounds in animals. Nobiletin (5,6,7,8,3′,4′-
hexamethoxyflavone) has a molecular formula of C21H22O8. Tangeretin (5,6,7,8,4′-
pentamethoxyflavone) has a molecular formula of C20H20O7. The bioavailability of PMFs is 
considered to be high in comparison to other citrus flavonoids because of the lipophilic 
nature of the multiple methoxy groups on the PMF structure. The smaller methoxyflavones, 
sinensetin, eupatorin and rutin, with one to three methoxy groups and without any 
hydroxyl groups, have been much less studied.  
3. Biological role of PMFs 
3.1 Metabolic syndrome 
Metabolic syndrome refers to a group of risk factors that increase the risk for heart disease 
and diabetes. The main risk factors of metabolic syndrome include central obesity, insulin 
resistance, hypertension and cholesterol abnormalities. Obesity contributes to insulin 
resistance, which has been proposed as the major underlying cause of type II diabetes, 
dyslipidemia, hypertension, and atherosclerosis (Kopelman, 2000). 
Results from previous experimental and clinical studies have suggested that citrus PMFs 
may improve glycemic control and reduce insulin resistance (Kurowska & Manthey, 2004., 
Miyata et al., 2011; Li et al., 2006; Judy et al., 2010). 
It is known that an increase in the number and size of adipocytes in adipose tissues leads to 
obesity-related insulin resistance. In a recent study, both nobiletin and tangeretin were 
found to increase the secretion of adiponectin (insulin-sensitizing factor) and decrease the 
secretion of MCP-1 (insulin-resistance factor) in 3T3-L1 adipocytes demonstrated by lower 
intracellular triglyceride levels as compared to vehicle-treated adipocytes. Further, nobiletin 
also decreased the secretion of resistin, which serves as an insulin-resistance factor (Miyata 
et al., 2011).  
Mulvihill & Huff, 2011, reported on the ability of nobiletin to improve whole-body insulin 
sensitivity and decrease hepatic gluconeogenesis induced in Ldlr-/- mice when fed a high-fat 
Western type diet. This effect of nobiletin was achieved by both an increase in peripheral 
glucose disposal and enhanced suppression of hepatic glucose production by insulin 
(Mulvihill & Huff, 2011). Prevention of insulin resistance, glucose intolerance and adiposity 
required 0.3% nobiletin suggesting that prevention of obesity and improved glucose 
tolerance by nobiletin are linked (Mulvihill & Huff, 2011).  
Furthermore, in Ldlr-/- mice, nobiletin supplementation reduced bodyweight, very low 
density lipoprotein cholesterol–triglyceride secretion and improved dyslipidemia. A 
study by Lee et al., 2010 suggested that nobiletin improved hyperglycemia and insulin 
resistance in obese diabetic ob/ob mice by regulating expression of glucose transporter 
(Glut) 4 levels in the whole plasma membrane, white adipose tissue (WAT) and muscle, 
and by regulating expression of adipokines in WAT. In addition, a mixture of nobiletin 
and tangeretin were found to regulate glucose metabolism in hamsters with fructose-
induced insulin resistance by modulating adipokines (Li et al., 2006). In this study PMF 
supplementation also reduced triglyceride content in both the liver and heart and was 
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able to significantly suppress serum tumor necrosis factor-ǂ (TNF-ǂ), interferon-Ǆ (INF-Ǆ), 
interleukin-1ǃ (IL-1ǃ) and interleukin-6 (IL-6) expression and increased serum 
adiponectin protein in insulin resistant hamsters. Additionally, in a study in hamsters 
with insulin resistance induced by feeding 60% fructose, the addition of 1% PMFs 
improved glucose tolerance, as demonstrated by the reduced area under the curve (AUC) 
measured after the intra-peritoneal injection of glucose (3g/kg body weight)(Kurowska & 
Manthey, 2004).  
In a recent study, the anti-diabetic potential of Diabetinol®, a dietary supplement 
consisting of >62% PMF extract from dried fruit and orange peel, composed mainly of 
nobiletin and tangeretin in a 4:1 ratio, was tested in fructose induced insulin resistant 
male Syrian golden hamsters. The Diabetinol® treatment group and positive control group 
were fed a fructose-enriched diet for three weeks to induce hypertriglyceridemia and 
insulin resistance (Taghibiglou et al., 2000). Hamsters (n=18) were fed regular chow, 60% 
fructose or a 60% fructose diet + 1% Diabetinol®. At the end of the study (Day 49), 
hamsters fed 60% fructose + 1% Diabetinol® demonstrated lower blood glucose, total 
cholesterol and triacylglycerol levels as compared to the fructose-fed animals (Judy et al., 
2010).  
3.2 Effect of Diabetinol
® 
on symptoms of metabolic syndrome – A human pilot study 
3.2.1 Subjects and study design 
The objective of the study was to investigate the efficacy of Diabetinol® (2 × 525 mg/day) vs. 
Placebo (Cellulose, 2 × 525mg/day) in glycemic control and management of risk factors of 
metabolic syndrome when supplemented for 12 weeks. Nineteen subjects with impaired 
fasting glucose (IFG) on stable oral medications were presented with a standard oral glucose 
challenge for the study.  
The study was a randomized, double-blind, placebo-controlled study. Subjects included 
were between ages of 18-75 years and had a body mass index (BMI) 25.0 to 39.9kg/m2, were 
weight stable (for 3 months prior to study), had a fasting glucose level between 6.1 and 
9.0mmol/L (109.8–162.0mg/dL), and a HbA1c level<7%. Subjects were excluded from 
participating if they were diabetic and required insulin therapy (Judy et al., 2010).  
The study included 5 clinic visits, which occurred at screening, baseline (Day 0), day 28, 56 
and 84.  
At baseline (randomization visit) and at all other visits anthropometric measurements were 
recorded, and BMI and waist/hip ratio were calculated. Fasting blood was collected for the 
determination of glucose, insulin and HbA1c. An oral glucose tolerance test (OGTT), where 
subjects consumed 100g of a glucose beverage over a 10min period was conducted and 
blood samples collected at 30, 60, 120, 180 and 240min post glucose consumption for 
analysis of glucose and insulin. On day 84, prior to the OGTT an additional 10mL of blood 
was collected for serum chemistry, hematology and for the determination of the lipid 
profile.  
Fasting glucose, insulin, HbA1c and AUC glucose and insulin were compared within group 
and HbA1c levels between the two groups by Student’s t-test. Statistical significance was 
established at p<0.05. 
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3.2.2 Results  
Analysis of subject demographics demonstrated that baseline fasting glucose was not different 
between groups (Diabetinol® 130.33 ± 3.64 mg/dL and placebo 129.80 ± 8.52mg/dL) but was 
above acceptable levels (<100mg/dL) and indicated that subjects in both groups had mild 
hyperglycemia (100–150mg/dL). Baseline HbA1c levels were not significantly different 
between subjects on placebo and Diabetinol® (6.53 ± 0.22% and 6.39 ± 0.22%, respectively).  
At baseline, 28, 56 and 84 days the peak in the plasma glucose curve following the glucose 
challenge, occurred between 60 and 120min in subjects on Diabetinol® or placebo (Fig. 2 a 
and 2 b). After supplementation for 56 and 84 days the glucose response curve of subjects on 
the Diabetinol® group was blunted as compared to the levels in the baseline OGTT curve.  
(a)  
(b)  
Fig. 2. Plasma glucose response curves to a standard glucose tolerance test before and after 
28, 56 and 84 days of (a) Diabetinol® and (b) placebo supplementation. The plasma response 
curve at 84 days was significantly different (p<0.01) from baseline at 30, 60 and 120min for 
Diabetinol® by Student’s t-test. Each data point is represented as mean ± SEM. 
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Further, after 84 days of supplementation subjects on Diabetinol® demonstrated a significant 
reduction in plasma glucose at 30, 60 and 120min after the glucose challenge when 
compared to baseline (Day 0) plasma glucose levels after the OGTT (p<0.01). The plasma 
glucose response curves after a glucose challenge at 28, 56 and 84 days for subjects on the 
placebo were not significantly different from that of their baseline values (Fig. 2b). 
There was no significant difference in mean fasting glucose values at baseline or day 84 
between, Diabetinol® (from 130.33 ± 3.64mg/dL at baseline to 123.33 ± 6.70mg/dL) or 
placebo (129.80 ± 8.52 to 123.90 ± 5.04mg/dL) (Fig. 2a and b). 
There was an increase of 9.0mg/dL in mean plasma glucose on day 28 and a reduction of 
9.0mg/dL on Day 56, and a significant reduction of 56.0mg/dL (p<0.01) on day 84 from 
baseline in subjects on Diabetinol® compared to those on placebo (data not shown). A mean 
reduction in AUC of 127mg/dL/h from baseline to day 84 was demonstrated in the 
Diabetinol® group while there was a 10mg/dL/h increase in subjects in the placebo group. 
There was no difference in plasma HbA1c levels between placebo and Diabetinol® groups 
at baseline, day 28, 56 or 84 (Fig. 3). HbA1c levels are not expected to change for 3-4 
months after an intervention. However, in this study after 84days of supplementation 
decreasing trends in the HbA1c were observed in subjects supplemented with Diabetinol® 
compared to subjects on placebo. Fasting plasma insulin levels were not significantly 
different between subjects on placebo and Diabetinol® at baseline, day 28, 56 or 84 and did 
not change significantly from baseline to day 28, 56 or 84 in the Diabetinol® or placebo 
groups.  
 
Fig. 3. Plasma HbAlc levels for placebo and Diabetinol® after 28, 56 and 84 days of 
supplementation. Statistical analysis was determined using Student’s t-test. Each data point 
is represented as mean ± SEM. 
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There were no statistically significant differences between subjects on placebo and 
Diabetinol® at baseline for total plasma cholesterol, triacylglycerols, low density lipoprotein 
cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) levels (Fig. 4). This 
cohort of subjects had lipid levels which were higher than the clinically acceptable range for 
these parameters. Subjects in the Diabetinol®group demonstrated a 13.29% reduction in total 
cholesterol (p<0.01) and a 22.79% reduction in LDL-C (p<0.01) from baseline to 84 days (Fig. 
5a). There were no significant changes in the lipid profiles from baseline to day 84 in 
subjects on placebo (Fig. 5b). 
. 
 
 
 
Fig. 4. Baseline (Day 0) plasma lipids for placebo and Diabetinol®. Statistical analysis of 
plasma lipids were determined using Student’s t-test. Data points are represented as mean ± 
SEM. 
3.3 Hyperlipidemia 
Elevated blood total cholesterol, higher LDL-C and reduced HDL-C are established risk 
factors of cardiovascular disease. Interest in PMFs has increased in recent years because of 
strong evidence showing that PMFs might lower total cholesterol, triglycerides, LDL-C and 
increase HDL-C in a number of in-vivo (Kurowska & Manthey, 2004; Li et al., 2006), in-vitro 
(Kurowska & Manthey, 2002; Kurowska et al., 2004) and human studies (Kurowska et al., 
2000; Roza et al., 2007). 
Previous studies demonstrated that PMFs from citrus, especially tangeretin and nobiletin, 
produce hypolipidemic responses in cells (Kurowska & Manthey, 2002; Kurowska et al., 
2004) and animals (Kurowska & Manthey., 2004), and that they also normalize some 
metabolic defects associated with experimentally induced insulin resistance (Kurowska & 
Manthey, 2004). 
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(a)  
(b)  
Fig. 5. (a) ∗ Diabetinol® group plasma lipids levels after 84 days of supplementation 
compared to the baseline (Day 0) levels (b) placebo control group plasma lipids levels after 
84 days of supplementation compared to the baseline (Day 0) levels. ∗p<0.01, day 84 values 
are significantly different from baseline values by Student t-test. Each data point is 
represented as mean ± SEM. 
Cell culture studies, demonstrated that several natural and synthetic PMFs have the ability 
to inhibit the net secretion of apolipoprotein B (Apo-B) in human liver cell line HepG2 
(Kurowska & Manthey, 2002). In HepG2, tangeretin substantially reduced the secretion of 
Apo-B and the synthesis of triacylglycerols which was associated with the activation of 
peroxisome proliferator-activated receptor (PPAR). PPAR is the nuclear transcription factor 
which is known to possess positive regulatory impact on sugar, fatty acids and lipoprotein 
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metabolism (Kurowska et al., 2004). Nobiletin has been reported to inhibit macrophage 
acetylated LDL metabolism, resulting in the blockage of formation of macrophage foam-
cells, which are essential to atherosclerotic plaque formation (Whitman et al., 2005).  
Results from animal studies demonstrated that dietary supplementation with 1% tangeretin 
or 1% PMFs (largely tangeretin and nobiletin) significantly reduced serum total cholesterol, 
very low density lipoprotein cholesterol and LDL-C (by 19−27 and 32−40%, respectively) 
and also decreased serum and liver triglycerides in hamsters with diet-induced 
hypercholesterolemia (Kurowska & Manthey, 2004). Positive effects of PMFs were also 
reported with respect to adipocytokine production and PPAR in insulin resistant hamsters. 
The PMF supplementation showed a reversal in metabolic defects including a reduction in 
insulin level and an improvement in glucose tolerance, thus confirming their 
antiinflammatory and antidiabetic effects (Li et al., 2006). This action is speculated to occur 
via the inhibition of the synthesis of core protein Apo-B required for LDL synthesis in the 
liver (Borradaile et al., 1999). 
In human studies, the responses to dietary supplements containing citrus PMFs in subjects 
with moderate hypercholesterolemia and baseline characteristics consistent with metabolic 
syndrome, demonstrated that a four week period improved blood lipid profiles without 
causing any adverse effects (Kurowska et al., 2001). Previously lipid lowering effects were 
also seen in hypercholesterolemic subjects taking orange juice for four weeks (Kurowska et 
al., 2000). Consistently, in moderately hypercholesterolemic men, mixtures of nobiletin and 
tangeretin at a dose of 270 mg/day, in combination with tocotrienols (30 mg/day), reduced 
plasma LDL-C, Apo-B and triglycerides (Roza et al., 2007). This suggests that PMFs have 
substantial cholesterol and triacylglycerol lowering potential.  
4. The importance of pharmacokinetics studies of PMFs  
Pharmacokinetics is the study of the mechanisms of absorption, metabolism and routes of 
excretion of the metabolites of an administered drug or nutrient. Bioavailability of a 
nutrient is simply the quantity or fraction of the ingested dose that is absorbed. 
Pharmacokinetic studies on PMFs are important in identifying the composition of 
metabolites of administered supplements. They may also help in differentiating different 
supplements on the market which have different levels and ratios of PMFs (i.e. nobiletin, 
tangeretin). Additionally, these studies may further provide information regarding 
absorption and metabolism of different formulations (i.e. soft gel capsule, hard shell 
capsule etc).  
There are multiple challenges in the development of PMFs which must be overcome to 
increase their bioavailability. For example, PMFs exist as aglycones. The solubility of 
aglycone forms is low, which may lead to slower dissolution rates in addition to the fact that 
absorbed aglycones are rapidly conjugated to glucuronides and sulfates in the intestine and 
liver (Li et al., 2007). Therefore, it is important to perform systematic studies to demonstrate 
how changes in PMF structures affect solubility and dissolution rates. 
Previous studies in hamsters showed, that when they were fed a tangeretin-enriched diet for 
35 days, the main PMF metabolites identified in serum, urine and in liver tissue included 
dihydroxytrimethoxyflavone and monohydroxytetramethoxyflavone glucuronides and 
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aglycones (Kurowska & Manthey, 2004). This demonstrated considerable intestinal 
absorption of tangeretin based on urinary excretion of several metabolites. However, no 
unchanged (parental) tangeretin was detected in the circulating plasma (Kurowska & 
Manthey, 2004). 
In a recent study by Manthey et al., 2011, nobiletin and tangeretin were administered to rats 
by gavage and intraperitoneal (ip) injection. By using high-performance liquid 
chromatography−electrospray ionization−mass spectrometry (HPLC-ESI-MS), blood serum 
concentrations of metabolites were monitored. Over 24 hours, two metabolites of tangeretin 
and eight metabolites of nobiletin were detected with the administered compounds. Results 
from this study demonstrated that with identical oral doses nearly 10-fold higher absorption 
of nobiletin occurred in comparison to tangeretin. Further, in the blood serum, maximum 
levels of glucuronidated metabolites occurred later than nobiletin and tangeretin and 
occurred at higher concentrations than aglycone metabolites (Manthey et al., 2011). It is also 
confirmed in previous trials that overall expression of biological actions of nobiletin and 
tangeretin in animals is due to the biological actions of aglycone metabolites (Eguchi et al., 
2007; Li et al., 2007; Lai et al., 2008; Xiao et al., 2009). 
Wan & Walle, 2006, demonstrated that the flavonoid chrysin (5,7-dihydroxyflavone) has 
poor bioavailability, but when two hydroxyl groups in chrysin were methylated, as in 5,7-
dimethoxyflavone (5,7-DMF), using cofactors for glucuronidation, sulfation and oxidation,  
chrysin was rapidly metabolized within 20 minutes of incubation showing no parent 
compound at the end. In contrast, over the whole 60-min time-course studied, 5,7-DMF was 
found to be metabolically stable (Wen & Walle, 2006). Further, there is evidence of the role 
of different cytochrome P450 isozymes, in oxidative demethylation in PMFs metabolism 
(Koga et al., 2007; Breinholt et al., 2003). 
Results from these studies on oral bioavailability thus indicated that the methoxylated 
flavones have a great advantage over the nonmethylated flavones. Future studies are 
needed to investigate the biochemical factors influencing the pharmacokinetics of PMFs.  
5. Pharmacokinetics of PMFs in Sytrinol
® 
5.1 Sytrinol
®
: A proprietary supplement consisting of PMFs and Tocotrienols  
Sytrinol® is a proprietary supplement developed by KGK Synergize Inc and consists of PMFs, 
mainly tangeretin and nobiletin (1:1 v/v) and palm oil tocotrienols. Tocotrienols are a group of 
dietary constituents, which are analogues of tocopherol (vitamin E), found mainly in palm oil 
and cereal grains. Tocotrienol-rich fractions from palm oil usually contain tocotrienols ǂ, λ and 
∆, as well as 15-40% ǂ-tocopherol (Guthrie & Carroll, 1998). The cholesterol-lowering potential 
of PMFs and tocotrienols has been investigated in preclinical studies and in clinical trials 
(Kurowska et al., 2004; Kurowska & Manthey, 2004; Roza et al., 2007).  
5.2 Human bioavailability study of three Sytrinol
®
 formulations in healthy subjects 
5.2.1 Subjects & study design 
The objective of this study was to determine whether PMFs may be detected and quantified 
in serum obtained from healthy adults after a single dose administration of Sytrinol® 
capsules (containing 1053 mg of total PMFs). The study compared oral bioavailability of 
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three Sytrinol® formulations in healthy subjects. The endpoints were the determination of 
various pharmacokinetic parameters, specifically area under the concentration-time curve 
(AUC0-48h), time at maximum concentration (Tmax) and maximum serum concentration 
(Cmax) for each of tangeretin and nobiletin.  
The study was conducted as a randomized crossover trial. Ten healthy subjects, five  
men and five women, age 23  3 years, were recruited for the study. Prior to the start of 
the study, subjects had blood drawn for routine tests to confirm eligibility. All subjects 
were asked to avoid caffeine-containing products 12 h prior to the study and during the 
study.  
Subjects were administered a single dose of the first Sytrinol® product (either Sytrinol® soft 
gel capsules (Product A), Sytrinol®  powder hard shell capsules (Product B) or Sytrinol® 
hard shell capsules with added lecithin (Product C), containing 1053 mg of PMFs, largely 
tangeretin and nobiletin (1:1 v/v) and tocotrienols. Standard citrus-free meals (breakfast, 
lunch and dinner) were provided on each of the days of the multiple blood sampling. 
Participants took the second PMF product 14 days later and the third product after another 
14 day washout period.  
Peripheral blood was taken by venipuncture at time 0 (baseline), 0.25, 0.5, 1, 2, 4, 6, 8, 24 
and 48 hours after ingestion of Sytrinol® capsules. Quantitation of tangeretin and 
nobiletin in serum was done by Liquid chromatography/Mass spectrometry (Varian 1200 
L LC/MS/MS system equipped with ESI and APCI sources). The identities of these PMFs 
were verified by comparing fragment ion mass spectra of authentic tangeretin and 
nobiletin standards. 
5.2.2 Results 
The serum samples obtained from healthy subjects following oral administration of three 
different Sytrinol® formulations demonstrated detectable amounts of parental tangeretin 
and nobiletin. Tangeretin and nobiletin peaks were identified and quantitated in all serum 
samples collected after administration of Sytrinol® formulations A, B or C.  
Results demonstrated that for both tangeretin and nobiletin, the AUC0-48h and Cmax values 
were significantly higher (P<0.001) after administration of formulation A than after 
treatment with products B or C, suggesting greater bioavailability of formulation A vs. B or 
C (Tables 1 & 2). For all three formulations, the AUC0-48h values were higher for nobiletin 
than for tangeretin indicating that nobiletin might be more bioavailable than tangeretin. The 
time-concentration curves and pharmacokinetic results demonstrated that for both 
tangeretin and nobiletin, significantly higher AUC0-48h and Cmax values were obtained 
following the administration of formulation A than following the administration of either B 
or C (Figure 6 & 7). The effects of the Sytrinol® formulations A, B and C on AUC0-48h and 
Cmax of tangeretin and nobiletin derivatives are depicted in Figures 8 & 9. For nobiletin, the 
AUC0-48h values were 2.7-3.0 times higher for supplement A than for B or C whereas for 
tangeretin, the AUC0-48h values were 1.7-2.3 times higher for A than for B or C. Changes in 
mean serum concentrations of tangeretin and nobiletin products after a single-dose 
administration of Sytrinol® A, B or C formulations are shown in Figures 6 and 7. The Tmax 
values were not affected by the type of treatment and also were similar for tangeretin and 
nobiletin peaks (1.3-1.4 h).  
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 A B C P value 
Initial conc. (µg/L) 49.5 ± 10.6 63.5 ± 51.6 28.5 ± 20.8  
AUC0-48h(µg x 
min/L) 
4654.4 ± 
1929.3 
1538.0 ± 
249.3*** 
1715.0 ± 
914.2*** 
<0.0001 
Cmax (µg /L) 1006.4 ± 555.3 51.8 ± 18.8*** 63.7 ± 33.2*** <0.0001 
Tmax (h) 1.4 ± 0.5 1.48 ± 0.8 1.4 ± 0.6  
***A vs. B, C are significantly different (p<0.001) by ANOVA followed by Tukey’s test. 
Table 1. Pharmacokinetics of serum nobiletin (means ± SD). 
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Fig. 6. Changes in serum concentrations of nobiletin after a single dose administration of 
Sytrinol® formulations A, B and C (1053 mg PMFs per product) (means ± SEM).  
Capsules contained both PMFs in equal amounts, however, more nobiletin than tangeretin 
was generally found in the blood. The differences were particularly striking in blood 
samples collected after administration of supplements A and B (with the AUC0-48h ratios of 
nobiletin to tangeretin 1.85 and 1.42, respectively) but also tended to occur after the 
administration of C (with the nobiletin to tangeretin ratio 1.14). The results suggest that in 
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healthy human subjects, nobiletin might be more bioavailable than tangeretin. The 
pharmacokinetic results showed that in healthy human subjects, Sytrinol®  product A (Soft 
Gel) was significantly more bioavailable than the remaining two products, B (hard shell) 
and C (hard shell + lecithin). Formulation A differed from B and C in respect to AUC0-48h 
and Cmax but not in respect to Tmax, which was not affected by treatments. Our data also 
suggest that nobiletin present in Sytrinol® formulations is more bioavailable than tangeretin.  
 
 A B C P value 
Initial conc. (µg /L) 31.4 ± 5.7 37.2 ± 25.6 29.9 ± 21.6  
AUC0-48h (µg x min/L) 2509.6 ± 1092.8 1085.8 ± 198.8** 1499.3 ± 864.0* 0.0041 
Cmax (µg /L) 532.3 ± 335.7 76.4 ± 49.9*** 48.0 ± 30.1*** <0.0001 
Tmax (h) 1.3 ± 0.5 1.3 ± 0.8 1.2 ± 0.6  
*A vs. C is p<0.05, **A vs. B is p<0.01,  
***A vs. B, C are p<0.001 by ANOVA followed by Tukey’s test. 
Table 2. Pharmacokinetics of serum tangeretin (means ± SD) 
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Fig. 7. Changes in serum concentrations of tangeretin after a single-dose administration of 
Sytrinol® formulations A, B and C (1053 mg PMFs per each dose (means ± SEM). 
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Fig. 8. Effects of Sytrinol® formulations A, B and C on AUC0-48h of tangeretin and nobiletin 
(means ± SEM). Values significantly different by ANOVA followed by Tukey’s test.  
*A vs. C is p<0.05, **A vs. B is p<0.01, ***A vs. B, C are p<0.001. 
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Fig. 9. Effects of Sytrinol® formulations A, B and C on Cmax of tangeretin and nobiletin 
(means ± SEM). Values significantly different by ANOVA followed by Tukey’s test.  
***A vs. B, C are significantly different (p<0.001). 
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6. Conclusion 
Bioavailability of a drug or nutrient supplement is largely determined by the properties of 
the dosage form. Yet, further characterizations of the metabolism and the biochemical 
factors influencing these compounds’ pharmacokinetics are essential, especially as oral 
bioavailability appears to be a significant limiting factor to the efficacy of these and other 
citrus PMFs.  
Both nobiletin and tangeretin have demonstrated efficacy in metabolic syndrome and 
hyperlipidemia, but vary in their pharmacokinetic properties. Research has demonstrated 
that nobiletin has greater bioavailability and efficacy as compared to tangeretin.  
Diabetinol® was developed with this concept in mind in order to address metabolic 
syndrome and hyperlipidemia.  
The pharmacokinetic profiles of nobiletin and tangeretin were previously based on the 
detection and quantification of their metabolites. In this chapter we have presented data on 
the detection of the parental compound nobiletin and tangeretin and suggest that in future 
research it is important to determine these compounds in human pharmacokinetic studies. 
Differences in bioavailability among formulations of a given supplement may have clinical 
significance; thus, knowing whether nutrient or drug formulations are equivalent is 
essential in making reasonable conclusions.  
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